Phase I/II Study of Low-Dose Oral Clofarabine for the Treatment of IPSS [International Prognostic Scoring System] INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (Dysplastic Type) Patients Who Have Failed Hypomethylating Therapy

Trial Profile

Phase I/II Study of Low-Dose Oral Clofarabine for the Treatment of IPSS [International Prognostic Scoring System] INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (Dysplastic Type) Patients Who Have Failed Hypomethylating Therapy

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Clofarabine (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 May 2017 Status changed from completed to discontinued as Data analysis revealed sufficient data for safety and efficacy .
    • 18 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jul 2014 Planned End Date changed from 1 Jan 2014 to 1 Jun 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top